The U.S. Food and Drug Administration (FDA) has signaled a crackdown on compounded weight-loss drugs, sending shares of Hims & Hers Health tumbling 14.1% after-hours trade. The FDA's concerns center on quality, safety, and potential violations of federal law, particularly regarding the GLP-1 ingredients used in non-approved compounded drugs. This move comes as a win for Novo Nordisk, which has been losing market share to Eli Lilly and telehealth firms like Hims. The controversy arises from Hims' plan to offer a $49 weight-loss pill, which is a copy of Novo Nordisk's Wegovy, at a significantly lower price than the brand name. This pricing strategy has sparked debate over the safety and efficacy of compounded drugs, as they are not FDA-approved and have not undergone clinical trials. The FDA's enforcement options include warning letters, court injunctions, and administrative seizures, with the support of the Department of Justice. This action is a significant shift from the FDA's previous stance, which has been limited to warning letters for misleading advertising. The agency emphasizes the importance of addressing unsubstantiated claims and public health concerns, highlighting the risks associated with substandard ingredients and unlawful mass production of knockoff drugs. The controversy extends to the advertising of compounded drugs, with the FDA prohibiting claims that these products are generic versions or clinically proven, emphasizing the need for transparency and patient safety.
